Dr Alan L Morgan, MD | |
4 Vanderbilt Park Dr Ste 100, Asheville, NC 28803-2476 | |
(828) 258-0397 | |
(828) 258-3390 |
Full Name | Dr Alan L Morgan |
---|---|
Gender | Male |
Speciality | Internal Medicine |
Experience | 28 Years |
Location | 4 Vanderbilt Park Dr Ste 100, Asheville, North Carolina |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1245220532 | NPI | - | NPPES |
1245220532 | Medicaid | NC | |
5914217 | Medicaid | NC |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207R00000X | Internal Medicine | 9900955 (North Carolina) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
Kindred At Home | Asheville, NC | Home health agency |
Memorial Mission Hospital And Asheville Surgery Ce | Asheville, NC | Hospital |
Park Ridge Health | Hendersonville, NC | Hospital |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Carolina Internal Medicine Associates Pa | 8426034422 | 26 |
News Archive
A research report published in the September 2012 issue of the Journal of Leukocyte Biology offers a possible explanation of why some cancer vaccines are not as effective as hoped, while at the same time identifies a new therapeutic strategy for treating autoimmune problems. In the report, scientists suggest that cancer, even in the very early stages, produces a negative immune response from dendritic cells, which prevent lymphocytes from working against the disease.
PanGenetics, an antibody development company which is developing PG110, a humanized antibody to Nerve Growth Factor (NGF), today announced it has entered into an agreement with Abbott under which Abbott will acquire the global rights to this novel biologic. PG110 is currently in a Phase 1 clinical trial in patients with osteoarthritis and represents a promising new therapeutic for the treatment of chronic pain.
Researchers open the way for improved study of hepatitis C virus by devising a novel virus culture system that allows replication of patient-isolated virus in nontransformed hepatocytes, instead of culture-adapted virus strains in transformed cell lines.
Using two biocompatible parts, University at Buffalo researchers and their colleagues have designed a nanoparticle that can be detected by six medical imaging techniques.
Kadmon Pharmaceuticals LLC, and Nano Terra, Inc., today announced that they have entered into an agreement under which Kadmon has been granted a perpetual, worldwide exclusive license to three novel, clinical-stage product candidates owned by Nano Terra as well as rights to Nano Terra's drug discovery platform, Pharmacomer Technology.
› Verified 8 days ago
Entity Name | Carolina Internal Medicine Associates Pa |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1710058086 PECOS PAC ID: 8426034422 Enrollment ID: O20040629001069 |
News Archive
A research report published in the September 2012 issue of the Journal of Leukocyte Biology offers a possible explanation of why some cancer vaccines are not as effective as hoped, while at the same time identifies a new therapeutic strategy for treating autoimmune problems. In the report, scientists suggest that cancer, even in the very early stages, produces a negative immune response from dendritic cells, which prevent lymphocytes from working against the disease.
PanGenetics, an antibody development company which is developing PG110, a humanized antibody to Nerve Growth Factor (NGF), today announced it has entered into an agreement with Abbott under which Abbott will acquire the global rights to this novel biologic. PG110 is currently in a Phase 1 clinical trial in patients with osteoarthritis and represents a promising new therapeutic for the treatment of chronic pain.
Researchers open the way for improved study of hepatitis C virus by devising a novel virus culture system that allows replication of patient-isolated virus in nontransformed hepatocytes, instead of culture-adapted virus strains in transformed cell lines.
Using two biocompatible parts, University at Buffalo researchers and their colleagues have designed a nanoparticle that can be detected by six medical imaging techniques.
Kadmon Pharmaceuticals LLC, and Nano Terra, Inc., today announced that they have entered into an agreement under which Kadmon has been granted a perpetual, worldwide exclusive license to three novel, clinical-stage product candidates owned by Nano Terra as well as rights to Nano Terra's drug discovery platform, Pharmacomer Technology.
› Verified 8 days ago
Mailing Address | Practice Location Address |
---|---|
Dr Alan L Morgan, MD 4 Vanderbilt Park Dr Ste 100, Asheville, NC 28803-2476 Ph: (828) 258-0397 | Dr Alan L Morgan, MD 4 Vanderbilt Park Dr Ste 100, Asheville, NC 28803-2476 Ph: (828) 258-0397 |
News Archive
A research report published in the September 2012 issue of the Journal of Leukocyte Biology offers a possible explanation of why some cancer vaccines are not as effective as hoped, while at the same time identifies a new therapeutic strategy for treating autoimmune problems. In the report, scientists suggest that cancer, even in the very early stages, produces a negative immune response from dendritic cells, which prevent lymphocytes from working against the disease.
PanGenetics, an antibody development company which is developing PG110, a humanized antibody to Nerve Growth Factor (NGF), today announced it has entered into an agreement with Abbott under which Abbott will acquire the global rights to this novel biologic. PG110 is currently in a Phase 1 clinical trial in patients with osteoarthritis and represents a promising new therapeutic for the treatment of chronic pain.
Researchers open the way for improved study of hepatitis C virus by devising a novel virus culture system that allows replication of patient-isolated virus in nontransformed hepatocytes, instead of culture-adapted virus strains in transformed cell lines.
Using two biocompatible parts, University at Buffalo researchers and their colleagues have designed a nanoparticle that can be detected by six medical imaging techniques.
Kadmon Pharmaceuticals LLC, and Nano Terra, Inc., today announced that they have entered into an agreement under which Kadmon has been granted a perpetual, worldwide exclusive license to three novel, clinical-stage product candidates owned by Nano Terra as well as rights to Nano Terra's drug discovery platform, Pharmacomer Technology.
› Verified 8 days ago
Dr. William R Harlan Iii, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 191 Biltmore Ave, Asheville, NC 28801 Phone: 828-254-0881 Fax: 828-254-1614 | |
Dr. Nellie E. L. Fleming, MD Internal Medicine Medicare: May Accept Medicare Assignments Practice Location: 509 Biltmore Ave, Asheville Hospitalist Group, Asheville, NC 28801 Phone: 828-213-4411 Fax: 828-285-9740 | |
Dr. Wade H Saunders Iii, M.D. Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 5 Vanderbilt Park Dr, Asheville, NC 28803 Phone: 828-274-6000 Fax: 828-277-6350 | |
Marianne Soufas, M.D. Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 68 Sweeten Creek Rd, Asheville, NC 28803 Phone: 828-274-9567 Fax: 828-255-2865 | |
Dr. Bryan J Pace, D.O. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 5 Vanderbilt Park Dr, Asheville, NC 28803 Phone: 828-274-6000 Fax: 828-274-6025 | |
Zachary Dillon Glenn, DO Internal Medicine Medicare: Medicare Enrolled Practice Location: 509 Biltmore Ave, Asheville, NC 28801 Phone: 828-213-1111 | |
Dr. Jeffrey Tyler Ramsey, DO Internal Medicine Medicare: Medicare Enrolled Practice Location: 123 Hendersonville Rd, Asheville, NC 28803 Phone: 828-407-2415 Fax: 828-412-4171 |